Camizestrant and atirmociclib for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that is 'ER-positive' (a cancer fueled by estrogen) and has worsened after at least one prior treatment.
- Your cancer must be measurable or able to be followed on scans (like CT or MRI).
- If you are premenopausal, you must start a medication to stop ovarian function at least 4 weeks before and during the study; if postmenopausal, you meet standard menopause criteria.
- You have not had 2 or more prior treatments with a type of drug called a CDK4/6 inhibitor (for example, palbociclib, ribociclib, or abemaciclib).
- You have not taken the study drugs camizestrant or atirmociclib before, and you are able to swallow pills.
- You are in fairly good overall health (ECOG score 0 or 1) and have no serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.